Plain-English translation of NCT07670130 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Researchers are studying how venetoclax — a medication used to treat newly diagnosed acute myeloid leukemia — works differently in different patients. Even though everyone receives the same standard dose, blood levels of this medication vary widely from person to person, which means some patients may get too much (causing severe side effects) while others get too little (reducing its effectiveness). This study will collect blood samples to understand these differences and help doctors personalize doses in the future.
Right now, all patients take the same fixed dose of this medication, but doctors know that people's bodies process it very differently based on their liver function, kidney function, other medications they're taking, and genetic factors. By measuring actual drug levels in the blood and seeing which patients do best, researchers hope to shift from a one-size-fits-all approach to a personalized approach that gives each patient the dose that works best for them.
You likely qualify if…
You likely don't qualify if…
You will receive the standard medication combination (venetoclax plus azacitidine) as decided by your treating doctor — the study does not change how you are treated. Over about three weeks, you will have blood samples drawn on specific days (days 8, 15, and 22) to measure how much medication is in your bloodstream. Researchers will then analyze these samples alongside your medical records to understand how your body processes the medication and how it relates to your response to treatment. You will continue with routine follow-up visits and care as part of your regular leukemia treatment.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
China